Cargando…
Effectiveness of an inactivated Covid-19 vaccine with homologous and heterologous boosters against Omicron in Brazil
The effectiveness of inactivated vaccines (VE) against symptomatic and severe COVID-19 caused by omicron is unknown. We conducted a nationwide, test-negative, case-control study to estimate VE for homologous and heterologous (BNT162b2) booster doses in adults who received two doses of CoronaVac in B...
| Autores principales: | , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group UK
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9537178/ https://www.ncbi.nlm.nih.gov/pubmed/36202800 http://dx.doi.org/10.1038/s41467-022-33169-0 |
| _version_ | 1784803142138855424 |
|---|---|
| author | Ranzani, Otavio T. Hitchings, Matt D. T. de Melo, Rosana Leite de França, Giovanny V. A. Fernandes, Cássia de Fátima R. Lind, Margaret L. Torres, Mario Sergio Scaramuzzini Tsuha, Daniel Henrique David, Leticia C. S. Said, Rodrigo F. C. Almiron, Maria de Oliveira, Roberto D. Cummings, Derek A. T. Dean, Natalie E. Andrews, Jason R. Ko, Albert I. Croda, Julio |
| author_facet | Ranzani, Otavio T. Hitchings, Matt D. T. de Melo, Rosana Leite de França, Giovanny V. A. Fernandes, Cássia de Fátima R. Lind, Margaret L. Torres, Mario Sergio Scaramuzzini Tsuha, Daniel Henrique David, Leticia C. S. Said, Rodrigo F. C. Almiron, Maria de Oliveira, Roberto D. Cummings, Derek A. T. Dean, Natalie E. Andrews, Jason R. Ko, Albert I. Croda, Julio |
| author_sort | Ranzani, Otavio T. |
| collection | PubMed |
| description | The effectiveness of inactivated vaccines (VE) against symptomatic and severe COVID-19 caused by omicron is unknown. We conducted a nationwide, test-negative, case-control study to estimate VE for homologous and heterologous (BNT162b2) booster doses in adults who received two doses of CoronaVac in Brazil in the Omicron context. Analyzing 1,386,544 matched-pairs, VE against symptomatic disease was 8.6% (95% CI, 5.6–11.5) and 56.8% (95% CI, 56.3–57.3) in the period 8–59 days after receiving a homologous and heterologous booster, respectively. During the same interval, VE against severe Covid-19 was 73.6% (95% CI, 63.9–80.7) and 86.0% (95% CI, 84.5–87.4) after receiving a homologous and heterologous booster, respectively. Waning against severe Covid-19 after 120 days was only observed after a homologous booster. Heterologous booster might be preferable to individuals with completed primary series inactivated vaccine. |
| format | Online Article Text |
| id | pubmed-9537178 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Nature Publishing Group UK |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-95371782022-10-08 Effectiveness of an inactivated Covid-19 vaccine with homologous and heterologous boosters against Omicron in Brazil Ranzani, Otavio T. Hitchings, Matt D. T. de Melo, Rosana Leite de França, Giovanny V. A. Fernandes, Cássia de Fátima R. Lind, Margaret L. Torres, Mario Sergio Scaramuzzini Tsuha, Daniel Henrique David, Leticia C. S. Said, Rodrigo F. C. Almiron, Maria de Oliveira, Roberto D. Cummings, Derek A. T. Dean, Natalie E. Andrews, Jason R. Ko, Albert I. Croda, Julio Nat Commun Article The effectiveness of inactivated vaccines (VE) against symptomatic and severe COVID-19 caused by omicron is unknown. We conducted a nationwide, test-negative, case-control study to estimate VE for homologous and heterologous (BNT162b2) booster doses in adults who received two doses of CoronaVac in Brazil in the Omicron context. Analyzing 1,386,544 matched-pairs, VE against symptomatic disease was 8.6% (95% CI, 5.6–11.5) and 56.8% (95% CI, 56.3–57.3) in the period 8–59 days after receiving a homologous and heterologous booster, respectively. During the same interval, VE against severe Covid-19 was 73.6% (95% CI, 63.9–80.7) and 86.0% (95% CI, 84.5–87.4) after receiving a homologous and heterologous booster, respectively. Waning against severe Covid-19 after 120 days was only observed after a homologous booster. Heterologous booster might be preferable to individuals with completed primary series inactivated vaccine. Nature Publishing Group UK 2022-10-06 /pmc/articles/PMC9537178/ /pubmed/36202800 http://dx.doi.org/10.1038/s41467-022-33169-0 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
| spellingShingle | Article Ranzani, Otavio T. Hitchings, Matt D. T. de Melo, Rosana Leite de França, Giovanny V. A. Fernandes, Cássia de Fátima R. Lind, Margaret L. Torres, Mario Sergio Scaramuzzini Tsuha, Daniel Henrique David, Leticia C. S. Said, Rodrigo F. C. Almiron, Maria de Oliveira, Roberto D. Cummings, Derek A. T. Dean, Natalie E. Andrews, Jason R. Ko, Albert I. Croda, Julio Effectiveness of an inactivated Covid-19 vaccine with homologous and heterologous boosters against Omicron in Brazil |
| title | Effectiveness of an inactivated Covid-19 vaccine with homologous and heterologous boosters against Omicron in Brazil |
| title_full | Effectiveness of an inactivated Covid-19 vaccine with homologous and heterologous boosters against Omicron in Brazil |
| title_fullStr | Effectiveness of an inactivated Covid-19 vaccine with homologous and heterologous boosters against Omicron in Brazil |
| title_full_unstemmed | Effectiveness of an inactivated Covid-19 vaccine with homologous and heterologous boosters against Omicron in Brazil |
| title_short | Effectiveness of an inactivated Covid-19 vaccine with homologous and heterologous boosters against Omicron in Brazil |
| title_sort | effectiveness of an inactivated covid-19 vaccine with homologous and heterologous boosters against omicron in brazil |
| topic | Article |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9537178/ https://www.ncbi.nlm.nih.gov/pubmed/36202800 http://dx.doi.org/10.1038/s41467-022-33169-0 |
| work_keys_str_mv | AT ranzaniotaviot effectivenessofaninactivatedcovid19vaccinewithhomologousandheterologousboostersagainstomicroninbrazil AT hitchingsmattdt effectivenessofaninactivatedcovid19vaccinewithhomologousandheterologousboostersagainstomicroninbrazil AT demelorosanaleite effectivenessofaninactivatedcovid19vaccinewithhomologousandheterologousboostersagainstomicroninbrazil AT defrancagiovannyva effectivenessofaninactivatedcovid19vaccinewithhomologousandheterologousboostersagainstomicroninbrazil AT fernandescassiadefatimar effectivenessofaninactivatedcovid19vaccinewithhomologousandheterologousboostersagainstomicroninbrazil AT lindmargaretl effectivenessofaninactivatedcovid19vaccinewithhomologousandheterologousboostersagainstomicroninbrazil AT torresmariosergioscaramuzzini effectivenessofaninactivatedcovid19vaccinewithhomologousandheterologousboostersagainstomicroninbrazil AT tsuhadanielhenrique effectivenessofaninactivatedcovid19vaccinewithhomologousandheterologousboostersagainstomicroninbrazil AT davidleticiacs effectivenessofaninactivatedcovid19vaccinewithhomologousandheterologousboostersagainstomicroninbrazil AT saidrodrigofc effectivenessofaninactivatedcovid19vaccinewithhomologousandheterologousboostersagainstomicroninbrazil AT almironmaria effectivenessofaninactivatedcovid19vaccinewithhomologousandheterologousboostersagainstomicroninbrazil AT deoliveirarobertod effectivenessofaninactivatedcovid19vaccinewithhomologousandheterologousboostersagainstomicroninbrazil AT cummingsderekat effectivenessofaninactivatedcovid19vaccinewithhomologousandheterologousboostersagainstomicroninbrazil AT deannataliee effectivenessofaninactivatedcovid19vaccinewithhomologousandheterologousboostersagainstomicroninbrazil AT andrewsjasonr effectivenessofaninactivatedcovid19vaccinewithhomologousandheterologousboostersagainstomicroninbrazil AT koalberti effectivenessofaninactivatedcovid19vaccinewithhomologousandheterologousboostersagainstomicroninbrazil AT crodajulio effectivenessofaninactivatedcovid19vaccinewithhomologousandheterologousboostersagainstomicroninbrazil |